Clinical trials: TIPS Insertion
Liver Cirrhosis, Refractory Ascites in Patients With Cirrhosis
Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome
The hypothesis is that in patients with cirrhosis and refractory ascites candidate to TIPS, and sarcopenia (identified by a PMA ≤16 cm² at the level of L3), who are at high-risk of 6-month mortality after TIPS placement, a…
- Conditions
- Liver Cirrhosis, Refractory Ascites in Patients With Cirrhosis, Sarcopenia in Liver Cirrhosis
- Trial name
- NS-TIPS (NCT06814626)
- Testing
- 12-week nutritional intervention with Friliver dispensing, 12-week nutritional intervention with personalized diet, 12-week nutritional intervention with diet diary to report foods eaten.
- Where
- 2 sites in Italy, Switzerland
- Volunteers
- 72 people
- Sponsor
- The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement
ALTA is a multicenter consortium focused on the management of portal hypertension. ALTA TIPS is a longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement.
- Trial name
- NCT03973372
- Where
- 14 sites in United States
- Volunteers
- 852 people
- Sponsor
- University of Texas Southwestern Medical Center
Hypertension, Portal
Virtual Imaging-based Early Portal Pressure Gradient (vePPG) (CHESS1702)
Portal pressure gradient (PPG) above 12 mmHg after transjugular intrahepatic portosystemic shunt (TIPS) increases the risk of portal hypertension complications.
- Trial name
- vePPG (NCT03177499)
- Testing
- Invasive PPG
- Where
- 10 sites in China
- Sponsor
- Nanfang Hospital, Southern Medical University
MASLD, Liver Cirrhosis, Alcoholic
Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients With Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement
The aim of this clinical trial is to investigate the development of cardiac decompensation following transjugular intrahepatic portosystemic shunt (TIPSS) implantation in order to draw conclusions for future treatment methods or…
- Conditions
- MASLD, Liver Cirrhosis, Alcoholic, Cirrhosis of Liver, Heart Decompensation
- Trial name
- EVALUATION (NCT06814990)
- Testing
- Cardiac MRI, Blood samples, Echocardiography
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Stephanie Gräger
Hepatic Encephalopathy, Cirrhosis, Liver
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration as minimal HE (MHE), covert HE (grade I), or…
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension, Liver Diseases
- Trial name
- PEARL (NCT04073290)
- Testing
- Rifaximin 550 milligram Oral Tablet [XIFAXAN], Lactulose 667 milligram/milliliter Oral Solution
- Where
- 6 sites in Belgium, Netherlands
- Volunteers
- 238 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Liver Cirrhosis, Portal Hypertension
Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement
Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients…
- Trial name
- PORTHEMOST (NCT07439939)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhotic Patients Undergoing TIPS Placement
A RCT COMPARING LACTULOSE AND RIFAXIMIN ASSOCIATED WITH A VEGETABLE DIET IN THE PREVENTION OF POST-TIPS OVERT HEPATIC ENCEPHALOPATHY
This is a randomized controlled trial whose purpose is to evaluate the efficacy of therapy with lactulose and rifaximin associated with a vegetable diet in the prevention of post-TIPS hepatic encephalopathy.
- Trial name
- NCT02931123
- Testing
- lattulose and rifaximine
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Roma La Sapienza
Hepatic Encephalopathy (HE), TIPS
UDCA to Prevent Post-TIPS Hepatic Encephalopathy
Hepatic encephalopathy (HE) commonly occurs after transjugular intrahepatic portosystemic shunt (TIPS). Ursodeoxycholic acid (UDCA) has been reported to alleviate neurodegenerative disease recently.
- Trial name
- THEUDCA (NCT07273734)
- Testing
- Ursodeoxycholic Acid (UDCA), Lactulose
- Where
- China
- Volunteers
- 270 people
- Sponsor
- West China Hospital
Cirrhosis, Refractory Ascites
Personalized Nutritional Intervention in Patients Undergoing TIPS Insertion for Refractory Ascites to Prevent Overt Hepatic Encephalopathy
This study will evaluate whether a nutritional intervention is better than another to reduce the incidence of overt hepatic encephalopathy in patients undergoing TIPS insertion for refractory ascites.
- Conditions
- Cirrhosis, Refractory Ascites, TIPS Insertion
- Trial name
- SUPPRESS-HE (NCT07634237)
- Testing
- High Energy and High Protein Diet 1, High Energy and High Protein Diet 2
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre